About Morphocell Technologies
Morphocell Technologies is a company based in Montreal (Canada) founded in 2018. Morphocell Technologies has raised $50 million across 3 funding rounds from investors including CQDM, Invest Quebec and CDP Venture Capital. Morphocell Technologies offers products and services including ReLiver. Morphocell Technologies operates in a competitive market with competitors including NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Series A
Dec 01, 2025
-
Investors
CQDM
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Morphocell Technologies
Morphocell Technologies offers a comprehensive portfolio of products and services, including ReLiver.
Develops tissue for treating liver diseases via advanced engineering.
People of Morphocell Technologies
Unlock access to complete
Unlock access to complete
Funding Insights of Morphocell Technologies
Morphocell Technologies has successfully raised a total of $50M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Morphocell Technologies
Morphocell Technologies has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include CQDM, Invest Quebec and CDP Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CQDM is focused on facilitating biopharma innovation through funding.
|
Locked | Locked | Locked | |
|
Venture capital and fund of funds focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Morphocell Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Morphocell Technologies
Investment portfolio details for Morphocell Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Morphocell Technologies
Detailed financials for Morphocell Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Morphocell Technologies Comparisons
Peer comparison for Morphocell Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Morphocell Technologies
Morphocell Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of Morphocell Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Morphocell Technologies
Complete news archive for Morphocell Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Morphocell Technologies
Morphocell Technologies was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Morphocell Technologies is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Morphocell Technologies is a funded company, having raised a total of $50M across 3 funding rounds to date.
Morphocell Technologies was founded in 2018 in Montreal, Canada, within the biotechnology sector. ReLiver, an engineered liver tissue, is utilized to create an implantable device for acute-on-chronic liver failure, an extracorporeal bio-artificial liver device, and in vitro assays for drug discovery. Operations focus on advancing these medical technologies to address liver-related conditions.
Morphocell Technologies's top competitors include Sutro Biopharma, Nimbus Therapeutics and Avidity Biosciences.
Morphocell Technologies offers ReLiver.
Morphocell Technologies has 4 investors. Key investors include CQDM, Invest Quebec, CDP Venture Capital, and Genson Capital.